Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

多供应商多站点新型加速 MRI 松弛测量

• 批准号: 10677551
• 负责人: Xiaojuan Li
• 金额: $ 60.37万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10677551
• 关键词: 3-Dimensional; Acceleration; Acute; Address; Affect; Age; Atlases; Behavior Therapy; Biological Markers; Body Weight decreased; Body mass index; Calibration; Cartilage; Clinical; Clinical Protocols; Collaborations; Data; Data Analyses; Dedications; Degenerative polyarthritis; Development; Diagnosis; Diet; Disease; Disease Progression; Early Diagnosis; Early treatment; Evaluation; Exercise; Gender; Image; Impairment; Industrialization; Intervention; Magnetic Resonance Imaging; Maps; Measurement; Measures; Methods; Modeling; Morphology; Musculoskeletal; Patients; Persons; Pharmaceutical Preparations; Pilot Projects; Prevention; Prevention strategy; Prognosis; Protocols documentation; Quality of life; Reference Values; Relaxation; Risk; Scanning; Site; Source; Standardization; System; T2 weighted imaging; Techniques; Technology; Time; Travel; Uncertainty; Variant; Vendor; anterior cruciate ligament rupture; cancer imaging; cartilage degradation; clinical practice; clinical translation; early detection biomarkers; heart imaging; human subject; imaging biomarker; imaging modality; improved; joint function; liver imaging; multi-site trial; musculoskeletal imaging; neural; neuroimaging; novel; palliation; precision medicine; quantitative imaging; synergism; tool; treatment effect

PROJECT SUMMARY/ABSTRACT MRI relaxometry has been applied to improve early diagnosis and prognosis for a wide range of diseases. However, one typical obstacle of integrating quantitative MRI into clinical protocols is the long acquisition time. Furthermore, it is an essential but sometimes overlooked step to investigate quantification variability across sites and MR systems in order to validate MR imaging biomarkers and to apply the measures in large scale multi- vendor multi-site trials. Specifically, there is a lack of systematic evaluation of inter-vendor inter-site variability of T1ρ imaging, even though it has been widely applied in neural-, liver-, cardiac-, oncology-, and musculoskeletal- (MSK) imaging. Neither commercial T1ρ phantoms are available. The proposed study is addressing these significant gaps and aims to develop and cross-validate novel fast MR T1ρ and T2 imaging methods on MR systems from multiple vendors, followed by feasibility evaluation in patients at risk for osteoarthritis. Osteoarthritis (OA) affects over 27 million people in the US. No disease modifying OA drugs (DMOADs) are available, despite extensive effort. One hurdle for developing DMOADs is the lack of sensitive and reliable non-invasive biomarkers that can detect treatment effects over a short time window. Such biomarkers would also benefit clinical practice by identifying patients at risk for developing OA or at an early disease stage, when behavior modification strategies are shown to be most effective in slowing down the disease progression. There is a pressing, unmet clinical need for robust assessment of early degeneration, which is critical to support a paradigm shift of OA management from palliation of late disease towards prevention through early diagnosis and early treatment/interventions. Cartilage MR T1ρ and T2 measures have been shown to be promising imaging biomarkers for early cartilage degeneration. However, many challenges remain to clinically applying these techniques, including lack of standardized acquisition and analysis methods, long acquisition time, and uncertainty of variations between different MR systems. In this study, we will develop novel accelerated T1ρ and T2 imaging methods, implement these techniques on MR systems of three major vendors (Siemens, GE and Philips), systematically evaluate inter-vendor inter-site variation of these measures using dedicated T1ρ and T2 calibration phantoms (to be developed in this study) and traveling subjects, investigate the source(s) and magnitude of the differences, explore methods to mitigate the variability, and demonstrate the feasibility of the newly developed acceleration techniques to quantify cartilage degeneration longitudinally in a multi-vendor setting. Successful implementation of the proposed study will provide a full package of T1ρ and T2 imaging that will be ready for dissemination and will help to pave the way towards large-scale multi-vendor, multi-site trials using T1ρ and T2 imaging, facilitate clinical translation of these quantitative MR techniques, and ultimately transform patient management of OA and other disorders using quantitative imaging biomarkers.

项目摘要/摘要 磁共振弛豫计量学已被应用于改善多种疾病的早期诊断和预后。 然而，将定量MRI集成到临床方案中的一个典型障碍是较长的采集时间。 此外，调查不同地点的量化可变性是一个重要但有时被忽视的步骤。 和磁共振系统，以验证磁共振成像生物标志物并将这些措施应用于大规模多 供应商多点试验。具体地说，缺乏对供应商间站点间可变性的系统评估 T1ρ成像，尽管它已广泛应用于神经、肝脏、心脏、肿瘤学和肌肉骨骼- (MSK)成像。这两种商用T1ρ幻影都不可用。拟议的研究正在解决这些问题 重大差距，旨在开发和交叉验证新的快速磁共振T1、ρ和T2磁共振成像方法 来自多家供应商的系统，随后对有骨关节炎风险的患者进行可行性评估。骨性关节炎 (OA)在美国影响着2700多万人。目前还没有治疗骨性关节炎的药物(DMOADs)，尽管 广泛的努力。开发DMOADs的一个障碍是缺乏敏感和可靠的非侵入性生物标志物 可以在短时间窗口内检测到治疗效果。这些生物标志物也将有益于临床实践。 通过识别有患骨性关节炎风险的患者或在早期疾病阶段，当行为改变时 研究表明，这些策略在减缓疾病进展方面最为有效。有一种紧迫的，未得到满足的 临床需要对早期退行性变进行强有力的评估，这是支持骨性关节炎范式转变的关键 从晚期疾病的姑息到早诊断早预防的管理 治疗/干预。软骨MR、T1、ρ和T2测量已被证明是有前景的成像 早期软骨退变的生物标志物。然而，在临床上应用这些技术仍然存在许多挑战。 技术，包括缺乏标准化的采集和分析方法，采集时间长，以及 不同MR系统之间差异的不确定性。在这项研究中，我们将开发新型的加速T1ρ和 T2成像方法，在三家主要供应商(西门子、通用电气和 飞利浦)，使用专用的T1ρ和T2系统地评估这些指标的供应商间站点间差异 校准模体(将在本研究中开发)和旅行对象，调查来源(S)和 差异的大小，探索缓解变异性的方法，并论证 新开发的加速技术用于量化多供应商的纵向软骨退变 布景。拟议研究的成功实施将提供完整的T1、ρ和T2成像方案， 将为传播做好准备，并将有助于为大规模多供应商、多地点试验铺平道路 使用T1ρ和T2成像，促进这些定量磁共振技术的临床翻译，并最终 使用定量成像生物标记物改变患者对骨性关节炎和其他疾病的管理。